MetaCap

Candel Therapeutics Inc. (CADL)

NASDAQ: CADLHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

5.04-0.09 (-1.75%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CADL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$395.37M
EPS (TTM)
-$1.53
52-week range
4.35 – 14.00
Day range
4.90 – 5.31
Volume / Avg
1.72M / 1.26M
Beta
—

52-week range

$4.35$14.00

CADL stock today

Candel Therapeutics (CADL) closed at $5.04 on Nov 20, down 1.75% (-$0.09), versus the S&P 500's 3.70% decline. At this level, CADL sits near the bottom of its 52-week range of $4.35 to $14.00: 64.0% below the high, set on Aug 27, 2026 and 15.9% above the low. CADL is down 10.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 10.8%.

Candel Therapeutics has posted a net loss over the last twelve months (EPS of -$1.53), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Candel Therapeutics

Company profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Headquarters
Needham, MA
Employees
55
IPO year
2021

Financial highlights

Full financials

Candel Therapeutics reported a net loss of $38.2 million, compared with a loss of $55.2 million a year earlier. Diluted earnings per share came in at -$0.72.

Candel Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue———$125.00K$125.00K
Growth———0.00%0.00%
Net income$-38.18M$-55.18M$-37.94M$-18.79M$-36.12M
EPS (diluted)$-0.72$-1.74$-1.31$-0.65$-1.91

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$17.67+250.60%

  • Strong buy 0
  • Buy 10
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $11.00High $29.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.28 vs $-0.30
Surprise
+6.67%

CADL news

All CADL news

Candel Therapeutics peers

Health Care sector
CADL peer companies
CompanyPrice% ChgMarket capCompare
TVGNTevogen Inc.5.90-6.35%$405.20Mvs CADL
TECXTectonic Therapeutic Inc.20.73-1.47%$405.26Mvs CADL
PROKProKidney Corp. Class A1.04-1.89%$415.21Mvs CADL
IRLAIRulya Therapeutics Inc.39.88-0.15%$432.36Mvs CADL
ALECAlector Inc.2.34+1.52%$347.63Mvs CADL
FENCFennec Pharmaceuticals Inc.13.09-2.68%$462.14Mvs CADL
RGNXREGENXBIO Inc.7.16-0.28%$473.44Mvs CADL
SANASana Biotechnology Inc.1.59-8.62%$476.42Mvs CADL

Indexes, lists and sector

Candel Therapeutics stock FAQ

What is Candel Therapeutics's stock price today?

CADL last traded at $5.04 as of Nov 20, 4:00 PM EST, down 1.75% on the day. Prices are delayed at least 15 minutes.

Who is Candel Therapeutics's CEO?

Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. is the chief executive officer of Candel Therapeutics Inc., which has about 55 employees.

What is the CADL 52-week high?

The 52-week high for CADL is $14.00 and the 52-week low is $4.35. The stock is currently 64.0% below its high.

Compare CADL